Insights

Distressed asset Endo International PLC recently emerged from Chapter 11 as a new private entity, Endo, Inc., indicating a potential window for distressed asset recovery opportunities, restructuring services, or post-bankruptcy compliance and integration solutions.

Regulatory risk Recall activity involving 16 lots of Clonazepam points to heightened regulatory and quality assurance needs; opportunities exist for quality management systems, traceability, batch record optimization, and corrective action/preventive action (CAPA) software or services.

Strategic financing Recent $900 million committed financing from Goldman Sachs signals liquidity and potential M&A or asset divestiture activity, presenting chances to offer integration platforms, financial reporting tooling, or project management solutions for large-scale transactions.

Digital modernization Adoption of technologies like Tableau, Kubernetes, SQL Server, and cloud-adjacent tooling suggests openness to modernization, data analytics, and secure IT operations services, including data warehousing, analytics, and cloud-native devops support.

Brand and outreach Active marketing initiatives including branded TV spots and Xiaflex campaigns indicate ongoing commercial efforts; opportunities exist to provide marketing automation, campaign analytics, digital asset management, or physician/consumer engagement platforms.

Similar companies to Endo Pharmaceuticals

Endo Pharmaceuticals Tech Stack

Endo Pharmaceuticals uses 8 technology products and services including Tableau, Kubernetes, Microsoft SQL Server, and more. Explore Endo Pharmaceuticals's tech stack below.

Media & News

Endo Pharmaceuticals's Email Address Formats

Endo Pharmaceuticals uses at least 4 email formats:
Endo Pharmaceuticals Email FormatsExamplePercentage
Last.First@endo.comDoe.John@endo.com
72%
First.Last@endo.comJohn.Doe@endo.com
23%
First@endo.comJohn@endo.com
3%
LastFirst@endo.comDoeJohn@endo.com
2%

Frequently Asked Questions

What is Endo Pharmaceuticals's stock symbol?

Minus sign iconPlus sign icon
Endo Pharmaceuticals is a publicly traded company; the company's stock symbol is CNDO1.

What is Endo Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Endo Pharmaceuticals's official website is endo.com and has social profiles on LinkedIn.

How much revenue does Endo Pharmaceuticals generate?

Minus sign iconPlus sign icon
As of October 2026, Endo Pharmaceuticals's annual revenue is estimated to be $100M - $250M.

What is Endo Pharmaceuticals's NAICS code?

Minus sign iconPlus sign icon
Endo Pharmaceuticals's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Endo Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of October 2026, Endo Pharmaceuticals has approximately 364 employees across 5 continents, including North America, Asia and Europe. Key team members include Chief Financial Officer: M. B., Vice President Program Management, India: A. D. and Vice President And Associate General Counsel: D. M. Explore Endo Pharmaceuticals's employee directory with LeadIQ.

What industry does Endo Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Endo Pharmaceuticals operates in the Pharmaceutical Manufacturing industry.

What technology does Endo Pharmaceuticals use?

Minus sign iconPlus sign icon
Endo Pharmaceuticals's tech stack includes Tableau, Kubernetes, Microsoft SQL Server, Microsoft Active Directory, VMware vCenter, Qualys, Microsoft Teams and Coupa.

What is Endo Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Endo Pharmaceuticals's email format typically follows the pattern of Last.First@endo.com. Find more Endo Pharmaceuticals email formats with LeadIQ.
Endo Pharmaceuticals logo

Endo Pharmaceuticals

Pharmaceutical ManufacturingPennsylvania, United States201-500 Employees

Endo Pharmaceuticals is a mid-sized pharmaceutical manufacturer based in Malvern, Pennsylvania. It operates in the pharmaceutical manufacturing industry and employs hundreds of people. The company develops and markets therapies to address medical needs, including generic and branded medicines; in 2024 it launched tiopronin delayed-release tablets, a generic version of THIOLA EC.

In 2025, Endo announced the Spatial Computing Injection Simulator, described as a first-of-its-kind initiative for a pharmaceutical company. The company has also pursued branded advertising efforts, such as campaigns for Xiaflex curled fingers treatment, reflecting activity in marketing alongside product development.

Section iconCompany Overview

Website
endo.com
Stock Symbol
CNDO1
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
201-500

Section iconFunding & Financials

  • $100M - $250M

    Endo Pharmaceuticals's revenue is estimated to be in the range of $100M - $250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.